Takeda Unveils R&D, Commercial Realignments To Try For Post-Patent Gains

TOKYO - Takeda Pharmaceutical Co. Ltd.'s CEO has espoused R&D and promotional strategy shifts for the company, unveiling a 2011-2013 mid-range plan to overcome current and upcoming patent losses of its major products. The company expects to rebound to 2010 levels by 2015 on the back of more efficient marketing and R&D, but implementation of a corporate shift will be vital to its success